^
    13d
    A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) (clinicaltrials.gov)
    P1, N=26, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    nemtabrutinib (MK-1026)
    28d
    Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • nemtabrutinib (MK-1026)
    1m
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)
    1m
    A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2027 --> Dec 2028
    Trial completion date
    |
    nemtabrutinib (MK-1026)
    1m
    Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Jennifer Woyach
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • nemtabrutinib (MK-1026)
    2ms
    A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    nemtabrutinib (MK-1026)
    2ms
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)
    3ms
    Computational hybrid framework integrating clinical-mutation profiling and physics-based simulations to predict structural tolerance of Bruton tyrosine kinase (BTK) and sustained ARQ 531 binding. (PubMed, Curr Res Struct Biol)
    Finally, the total binding free energy (TBE) calculations revealed that ARQ531 exhibits broadly conserved binding energetics across clinically observed BTK mutants, with select variants (notably C481 substitutions) showing moderately enhanced stabilization relative to the wild type. These findings confirm that ARQ 531 remains a significant investigational therapy specifically for overcoming drug resistance in multiple leukemias and B-cell malignancies and can serve as a starting point for designing more robust and effective BTK inhibitors.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    nemtabrutinib (MK-1026)
    3ms
    waveLINE-006: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) (clinicaltrials.gov)
    P2, N=223, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    zilovertamab vedotin (MK-2140) • nemtabrutinib (MK-1026)
    3ms
    Nemtabrutinib, Bortezomib, and Rituximab for WM (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Seoul National University Hospital
    New P2 trial
    |
    Rituxan (rituximab) • bortezomib • nemtabrutinib (MK-1026)
    4ms
    A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) (clinicaltrials.gov)
    P1, N=32, Recruiting, Merck Sharp & Dohme LLC | N=16 --> 32
    Enrollment change
    |
    nemtabrutinib (MK-1026)
    5ms
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Dec 2025 --> Apr 2026
    Trial initiation date
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)